Exchange: NASDAQ·Updated 06:52 PM EST
ENGN logo

ENGN enGene Holdings Inc

$1.74
$0.02
(1.14%)
Today
Closed $1.74
$0.00
(0.00%)
After Hours
EarningsDec 22
Mkt Cap$116.61M
Vol556,726.00

About ENGN

enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.
50

Neutral Sentiment

How do you feel about ENGN?

BiotechSwings
Analysts are finally chasing $ENGN and ngl the data earned it up 26.7% Thursday while the sector fell 3.3%. LEGEND held 56% complete responses, 12 month responses doubled to 24% from 13%, rolling BLA starts by year end and Leerink flipped to Outperform at $5 today. trading near 2.30 today imo
4
focafoca99
$ENGN discloses Phase 2 LEGEND trial results and preliminary FY2026 cash of $245.8M in its 8-K filing.
2
GrumpySumurai
$ENGN might keep pumping, up 51% off the 10-day low on 4.4x its average volume after the updated bladder cancer data and the plan to start the BLA filing by year end. Worth noting both of its past pumps were followed by an offering though.
1
chicharrotrading
$ENGN $SILO 🔥 today's watchlist — 1 micro/nano-cap + 1 micro/nano-floater covered below. $ENGN (micro/nano-cap #20) 🚀 strong momentum, ⚠️ moderate risk | Healthcare/Biotechnology ($152.8M) 🔦 Chart flags a recent double top pattern — 🏭 FDA decision cycles Patent-cliff timing Health-policy debates — 🌍 Central-bank policy stance Interest-rate expectations Risk appetite — 📰 enGene Updates Pivotal Bladder Cancer Data, Names New CMO, Legal Chief (MT Newswires) — 🔴 External conditions: NEGATIVE $SILO (micro/nano-floater #8) 🚀 strong momentum, ⚠️ elevated risk | Healthcare/Biotechnology ($4.5M) — Float 1.6M sh shares 🔦 Chart flags a recent double top pattern — 🏭 FDA decision cycles Patent-cliff timing Health-policy debates — 🌍 National regulatory developments Policy headline sensitivity — 📰 Silo Pharma Acquires Software and IP From Norsight; Issues Warrant for 300,000 Shares at $1.51 (TradingView) — 🔴 External conditions: NEGATIVE
AlertsAndNews
$ENGN headline here enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC

Advertisement|Remove ads.